Tesla
TSLA
NVIDIA
NVDA
Advanced Micro Devices
AMD
Taiwan Semiconductor
TSM
Qualcomm
QCOM
US Stock MarketDetailed Quotes
HLVX HilleVax
- 2.090
- +0.010+0.48%
Close Jan 3 16:00 ET
- 2.090
- 0.0000.00%
Post 16:27 ET
104.09MMarket Cap-0.68P/E (TTM)
2.135High2.060Low316.42KVolume2.080Open2.080Pre Close661.94KTurnover1.06%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.56P/B62.54MFloat Cap1.55052wk Low--Dividend TTM29.92MShs Float24.420Historical High--Div YieldTTM3.61%Amplitude1.550Historical Low2.091Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet